Peptide Comparison
Tesamorelin vs GHRP-2
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Tesamorelin has stronger documented evidence (FDA-Approved) than GHRP-2 (Japan-Approved Diagnostic) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, Tesamorelin is the safer pick. GHRP-2 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Tesamorelin | GHRP-2 | |
|---|---|---|
| Class | GHRH analog (FDA-approved) | GHRP; ghrelin receptor agonist |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion | GHS-R1a agonist; strong GH release |
| Route | SC injection | SC / Intranasal |
| Half-life | ~26 min | ~15-30 min |
| Dosage (research) | 2 mg SC daily (FDA label) | 100-300 mcg SC 1-3x daily |
| Evidence tier | FDA-Approved | Japan-Approved Diagnostic |
| Research depth | 127 indexed | 148 indexed |
| Availability | Prescription | Research |
| Reported risks | Injection site reactions; hyperglycemia; joint pain; edema; elevated IGF-1 | Cortisol/prolactin increase; hunger; water retention |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Tesamorelin or GHRP-2?
Tesamorelin has stronger documented evidence (FDA-Approved) than GHRP-2 (Japan-Approved Diagnostic) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, Tesamorelin is the safer pick. GHRP-2 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between Tesamorelin and GHRP-2?
Tesamorelin is classed as GHRH analog (FDA-approved); GHRP-2 is classed as GHRP; ghrelin receptor agonist. Reported mechanism: Tesamorelin, Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion; GHRP-2, GHS-R1a agonist; strong GH release. Reported half-life: Tesamorelin, ~26 min; GHRP-2, ~15-30 min. Routes in published studies: Tesamorelin, SC injection; GHRP-2, SC / Intranasal.
Which has stronger evidence, Tesamorelin or GHRP-2?
Tesamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Tesamorelin is graded FDA-Approved, with 13 cited sources on its reference page and 127 indexed studies. GHRP-2 is graded Japan-Approved Diagnostic, with 1 cited source on its reference page and 148 indexed studies.
Which is more accessible, Tesamorelin or GHRP-2?
Tesamorelin is FDA-approved and GHRP-2 is not. Catalog status: Tesamorelin, Prescription; GHRP-2, Research. FDA lists GHRP-2 in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).
Are Tesamorelin and GHRP-2 ever combined?
Tesamorelin and GHRP-2 appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…